Tirzepatide Lowers Weight Across All Groups With Obesity

Posted by & filed under Uncategorized.

safety-lane.com 07105
chiropractic-lane.com
www.cbd-lane
NEWARK
http://www.healthy-lane.com/

Tirzepatide Lowers Weight Across All Groups With Obesity

Weight loss with tirzepatide was fairly uniform across different body mass index (BMI) ranges, ages, and number of obesity-related comorbidities in patients with overweight/obesity without type 2 diabetes.

These were the main findings in a session about tirzepatide — the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonist — for obesity, presented at ObesityWeek®.

In May, tirzepatide (Mounjaro), a once-weekly subcutaneous injection, was approved by the US Food and Drug Administration for glycemic control in patients with type 2 diabetes based on the SURPASS clinical trials.

Then in June, at the American Diabetes Association 2022 annual meeting, researchers reported “unprecedented” weight loss with tirzepatide in patients without type 2 diabetes, in the phase 3 SURMOUNT-1 clinical trial.

Louis J. Aronne, MD, Weill Cornell Medical College, New York City, presented findings from a prespecified analysis of BMI subgroups (oral abstract 110).

The four BMI subgroups were:

  • ≥ 27 to < 30 kg/m2 (overweight), mean initial weight 178 pounds, mean weight reduction 29 to 30 pounds

  • ≥ 30 to < 35 kg/m2 (class 1 obesity), mean initial weight 198 pounds, mean weight reduction 33 to 43 pounds

  • 35 to < 40 kg/m2 (class 2 obesity), mean initial weight 228 pounds, mean reduction 34 to 56 pounds

  • 40 kg/m2 (class 3 obesity), mean initial weight 280 pounds, mean weight reduction 44 to 64 pounds

ObesityWeek® 2022. Oral abstracts 109-112. Presented November 4, 2022.

via Blogger https://bit.ly/3UM0qd9